<DOC>
	<DOC>NCT02854618</DOC>
	<brief_summary>This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus</brief_summary>
	<brief_title>Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patients eligible for a treatment by everolimus in association with the exemestane Performance status of 0,1 or 2 according to the WHO Patients affected of a breast cancer advanced and\or metastatic HER2 negative expressing the hormonal receptor RH + menopausal Patients Psychiatric disease compromising the understanding of the information or the realization of the study Vulnerable people according to the law (minors, adults under protection, private persons of freedom) Histories of cancer in 5 years preceding the diagnosis (except breast cancer, squamouscell) Not menopausal women Unaffiliated people to the Social Security People being for the period of exclusion from another study Hypersensitivity in the active substance, in the other byproducts of the rapamycin or in one of the excipients. Symptomatic visceral achievement Legal incapacity or limited legal capacity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>